Stocks · Health care · Pharmaceutical Preparations

Sagimet Biosciences Inc.

SGMT Clue Score32
United States Fiscal year ends December CIK 0001400118 Results filed 11 Aug 2026

What the insiders did No buying or selling

By person

5 insiders · 0 transactions
12.0×

David Happel holds 12.0 times base salary in stock. $7.59M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what David Happel last reported holding, valued at $10.23, the price Series A Common Stock was last bought or sold at on the open market here, on 14 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
David Happel
President & CEO
—
—
—
741,570
$7.59M
+16.0%
Elizabeth Rozek
Chief Legal & Admin. Officer
—
—
—
224,414
$2.30M
+39.8%
Eduardo Bruno Martins
Chief Medical Officer
—
—
—
147,296
$1.51M
+81.4%
George Kemble
Director
—
—
—
62,161
$636.08K
−47.6%
Thierry Chauche
Chief Financial Officer
—
—
—
59,688
$610.78K
—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.